At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZLAB Zai Lab Ltd
Post-Mkt 05-19 19:03:13 EDT
18.37
-0.49
-2.60%
盘后18.75
+0.38+2.07%
16:18 EDT
High18.85Low18.22Vol626.59K
Open18.75D1 Closing18.86Amplitude3.34%
Mkt Cap2.06BTradable Cap2.01BTotal Shares112.35M
T/O11.60MT/O Rate0.57%Tradable Shares109.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
TIPRANKS  ·  05-19 13:15
CICC Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)
Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
MT Newswires Live  ·  05-18 22:44
Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
Zai Lab Shares Surge Over 5% in Late Trading as Zoci Receives FDA Fast Track Designation for Extrapulmonary Neuroendocrine Carcinoma
Stock News  ·  05-15
Zai Lab Shares Surge Over 5% in Late Trading as Zoci Receives FDA Fast Track Designation for Extrapulmonary Neuroendocrine Carcinoma
Zai Lab Announces Grant of Stock Options and Restricted Stock Units
Stock News  ·  05-12
Zai Lab Announces Grant of Stock Options and Restricted Stock Units
Zai Lab Shares Surge Over 5% in Early Trading as Zoci Receives FDA Fast Track Designation
Stock News  ·  05-12
Zai Lab Shares Surge Over 5% in Early Trading as Zoci Receives FDA Fast Track Designation
Hong Kong Stocks Open Higher, Tech and Gold Shares Gain; Kuaishou Surges Over 9%
Deep News  ·  05-12
Hong Kong Stocks Open Higher, Tech and Gold Shares Gain; Kuaishou Surges Over 9%
Stock Track | Zai Lab Soars 10.56% Intraday on FDA Fast Track Designation for Zoci Drug
Stock Track  ·  05-11
Stock Track | Zai Lab Soars 10.56% Intraday on FDA Fast Track Designation for Zoci Drug
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
MT Newswires Live  ·  05-11
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading
Stock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci
Stock Track  ·  05-11
Stock Track | Zai Lab Soars 6.45% in Pre-market on FDA Fast Track Designation for Zoci
Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas
MT Newswires Live  ·  05-11
Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas
UBS Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
TIPRANKS  ·  05-09
UBS Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)
Zai Lab Is Maintained at Buy by Citigroup
Dow Jones  ·  05-09
Zai Lab Is Maintained at Buy by Citigroup
Stock Track | Zai Lab Plummets 5.08% Intraday After Citi Cuts Price Target
Stock Track  ·  05-09
Stock Track | Zai Lab Plummets 5.08% Intraday After Citi Cuts Price Target
Citi Sticks to Its Buy Rating for Zai Lab (ZLAB)
TIPRANKS  ·  05-08
Citi Sticks to Its Buy Rating for Zai Lab (ZLAB)
Zai Lab price target lowered to $44 from $47 at Citi
TIPRANKS  ·  05-08
Zai Lab price target lowered to $44 from $47 at Citi
Zai Lab's Innovative Pipeline Nears Key Milestones, Unveiling Three Core Strengths for Potential Rebound
Stock News  ·  05-08
Zai Lab's Innovative Pipeline Nears Key Milestones, Unveiling Three Core Strengths for Potential Rebound
BUZZ-Zai Lab HK shares fall to 5-week low on weak Q1 results
Reuters  ·  05-08
BUZZ-Zai Lab HK shares fall to 5-week low on weak Q1 results
Zai Lab Reports $99.6 Million in Total Revenue for Q1 2026
Stock News  ·  05-07
Zai Lab Reports $99.6 Million in Total Revenue for Q1 2026
Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate
Benzinga  ·  05-07
Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate
Press Release: Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
Dow Jones  ·  05-07
Press Release: Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

Introduction

Company Name.
Zai Lab Ltd
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Issue price:
--